Telix Pharmaceuticals appointed David Gill as Chair of the Board effective September 1, 2026. Mr. Gill joined the company as a Non-Executive Director in May 2026 and succeeds Dr. Mark Nelson, who served as interim Chair and will remain on the Board. Telix is a commercial-stage global radiopharmaceutical company advancing targeted theranostics for cancer treatment.
